- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S3939
| Related Targets | ERK p38 MAPK K-Ras Raf JNK MEK Ras S6 Kinase MAP4K TAK1 |
|---|---|
| Other NF-κB Products | Omaveloxolone (RTA-408) DCZ0415 BAY 11-7082 (BAY 11-7821) JSH-23 QNZ (EVP4593) SC75741 Caffeic Acid Phenethyl Ester DHA (Dihydroartemisinin) Andrographolide Evodiamine |
|
In vitro |
DMSO
: 48 mg/mL
(198.12 mM)
Ethanol : 48 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 242.27 | Formula | C15H14O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 33626-08-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1=CC=C(C=C1)C=CC2=CC(=CC(=C2)O)O | ||
| Targets/IC50/Ki |
NF-κB
NLRP3
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01199250 | Not yet recruiting | Lynch Syndrome|Recurrent Uterine Corpus Carcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer |
Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
January 2100 | -- |
| NCT04662164 | Withdrawn | Type 2 Diabetes Patients |
Shanghai HEP Pharmaceutical Co. Ltd. |
December 2025 | Phase 1|Phase 2 |
| NCT06177132 | Not yet recruiting | Vestibular Disorder |
University Hospital Ghent|University Ghent |
November 2025 | Not Applicable |
| NCT03277170 | Not yet recruiting | Asthma; Status|Asthma in Children|Asthma Acute|Asthma Attack|Acute Asthma Exacerbation |
Vanderbilt University Medical Center |
September 1 2025 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.